About the Journal of Thyroid Cancer
A specialized peer-reviewed platform advancing molecular understanding of thyroid malignancies through rigorous pathophysiological research-from genetic drivers to biomarker discovery.
JTC curates research that illuminates how thyroid cancer works at the cellular and molecular level-not how to treat it. Our scope encompasses mechanistic studies that identify disease pathways, validate biomarkers for detection and prognosis, and develop experimental models that replicate thyroid cancer biology. This foundational knowledge provides the scientific basis upon which future therapeutic strategies may be built, but our editorial priority remains firmly anchored in mechanistic discovery.
Genetic mutations (BRAF, RAS, RET/PTC rearrangements), epigenetic modifications, chromosomal instability, and hereditary syndromes driving thyroid malignancy initiation.
MAPK/ERK, PI3K/AKT/mTOR, Wnt/β-catenin, and receptor tyrosine kinase pathways-mechanistic analysis of aberrant activation in thyroid carcinogenesis.
Immune cell infiltration, fibroblast activation, extracellular matrix remodeling, and paracrine signaling networks influencing tumor progression.
Molecular markers for disease detection, subtype classification, prognostic stratification, and recurrence prediction-emphasizing mechanistic rationale.
Altered glucose uptake, lipid metabolism, mitochondrial function, and metabolic reprogramming supporting thyroid cancer cell survival and proliferation.
Molecular mechanisms of EMT induction, transcription factor regulation, and phenotypic plasticity enabling invasion and metastatic potential.
VEGF signaling, endothelial cell recruitment, and vascular network formation supporting tumor growth and dissemination.
Checkpoint aberrations, cyclin/CDK imbalances, p53 pathway disruption, and resistance to programmed cell death in thyroid malignancies.
Cell line characterization, patient-derived xenografts, organoid cultures, and CRISPR-engineered models replicating thyroid cancer biology.
Understanding thyroid cancer pathophysiology requires dissecting the complex molecular cascades that drive disease progression. JTC publishes mechanistic investigations that:
- Identify novel molecular targets through genomic, transcriptomic, proteomic, and metabolomic profiling of thyroid malignancies.
- Elucidate signaling pathway crosstalk and feedback mechanisms that sustain aberrant cellular behavior in thyroid cancer.
- Validate biomarkers through mechanistic studies demonstrating biological relevance rather than correlative observation alone.
- Characterize tumor heterogeneity at single-cell resolution, revealing subpopulation-specific vulnerabilities and adaptive mechanisms.
- Investigate immune evasion strategies employed by thyroid cancer cells to escape host surveillance.
- Map spatial biology of thyroid tumors using imaging mass spectrometry, spatial transcriptomics, and multiplex immunofluorescence.
- Develop computational models integrating multi-omic datasets to predict disease trajectories and identify rate-limiting steps in carcinogenesis.
JTC offers three streamlined submission routes to accommodate diverse researcher workflows. All manuscripts undergo rigorous peer review by experts in thyroid cancer pathophysiology, molecular oncology, and experimental biology.
Online Portal Submission
Submit directly through our secure web interface. Upload manuscript files, supplementary data, and graphical abstracts with real-time tracking.
Access Submission Portal →Email Submission
Send manuscripts as Word or PDF attachments with a cover letter outlining mechanistic novelty and scope alignment.
Email: [email protected] →Manuscript Zone Platform
Create a secure author account for enhanced manuscript tracking, reviewer communication, and revision management.
Login to Manuscript Zone →JTC's editorial board comprises international experts in thyroid cancer molecular biology, endocrine oncology, genomics, and translational research. Our editors ensure that published manuscripts meet rigorous standards for experimental design, analytical validity, and mechanistic interpretation.
The peer review process emphasizes:
- Methodological rigor-appropriate controls, statistical power, reproducibility documentation
- Mechanistic depth-clear delineation of molecular pathways and causal relationships
- Data transparency-availability of raw data, analysis scripts, and reagent details
- Ethical compliance-institutional approvals, informed consent, and adherence to reporting standards (ARRIVE, MIQE, REMARK)
JTC operates under an open access framework, ensuring that thyroid cancer pathophysiology research is freely accessible to the global scientific community. Upon manuscript acceptance, authors pay an Article Processing Charge (APC) covering peer review coordination, production editing, XML/HTML conversion, DOI assignment, and perpetual hosting.
All content is published under Creative Commons licenses, permitting unrestricted use with proper attribution. This model accelerates knowledge dissemination and enables researchers worldwide to build upon mechanistic discoveries without financial barriers.
JTC has partnered with leading research institutions advancing thyroid cancer molecular biology:
- University of Puerto Rico
- Universite Libre De Bruxelles
- Northwestern University
- University of Wisconsin
- Fornaroli Hospital, Magenta, Italy
- European Institute of Oncology
- University of Milan
- Noguchi Thyroid Clinic and Hospital Foundation
- Keio University
- Eisai Headquarters
- Hospital Ángeles Tijuana
Advance Thyroid Cancer Pathophysiology Research
Join the global community of molecular biologists, cancer researchers, and pathophysiologists advancing mechanistic understanding of thyroid malignancies. Submit your discoveries to JTC and contribute to the foundational knowledge base driving future innovations.
